Elective gender selection of human embryos during IVF

Author(s):  
Gab Kovacs
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Alix Lenia v. Hammerstein ◽  
Matthias Eggel ◽  
Nikola Biller-Andorno

Abstract Background Recent scientific advances in the field of gene editing have led to a renewed discussion on the moral acceptability of human germline modifications. Gene editing methods can be used on human embryos and gametes in order to change DNA sequences that are associated with diseases. Modifying the human germline, however, is currently illegal in many countries but has been suggested as a ‘last resort’ option in some reports. In contrast, preimplantation genetic (PGD) diagnosis is now a well-established practice within reproductive medicine. Both methods can be used to prevent children from being born with severe genetic diseases. Main text This paper focuses on four moral concerns raised in the debate about germline gene editing (GGE) and applies them to the practice of PGD for comparison: Violation of human dignity, disrespect of the autonomy and the physical integrity of the future child, discrimination of people living with a disability and the fear of slippery slope towards immoral usage of the technology, e.g. designing children for specific third party interests. Our analysis did not reveal any fundamental differences with regard to the four concerns. Conclusion We argue that with regard to the four arguments analyzed in this paper germline gene editing should be considered morally (at least) as acceptable as the selection of genomes on the basis of PGD. However, we also argue that any application of GGE in reproductive medicine should be put on hold until thorough and comprehensive laws have been implemented to prevent the abuse of GGE for non-medical enhancement.


2021 ◽  
Author(s):  
Yuntao Xia ◽  
Veronica Gonzales-Pena ◽  
David Klein ◽  
Joe Luquette ◽  
Liezl Puzon ◽  
...  

Current preimplantation genetic testing (PGT) enables the selection of embryos based on fetal aneuploidy or the presence a small number of preselected disease-associated variants. Here we present a new approach that takes advantage of the improved genome coverage and uniformity of primary template-directed amplification (PTA) to call most early embryo genetic variants accurately and reproducibly from a preimplantation biopsy. With this approach, we identified clonal and mosaic chromosomal aneuploidy, de novo mitochondrial variants, and variants predicted to cause mendelian and non-mendelian diseases. In addition, we utilized the genome-wide information to compute polygenic risk scores for common diseases. Although numerous computational, interpretive, and ethical challenges, this approach establishes the technical feasibility of screening for and preventing numerous debilitating inherited diseases.


2006 ◽  
Vol 22 (3) ◽  
pp. 829-835 ◽  
Author(s):  
Paula J. Stokes ◽  
Judith A. Hawkhead ◽  
Richard K. Fawthrop ◽  
Helen M. Picton ◽  
Vinay Sharma ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document